MiniMed 780G Advanced Hybrid Closed-Loop System Outcomes According to Pubertal Status: Awesome Study Group Real-Life Experience
Authors' conclusion
The use of AHCL enabled improvements in TIR70-180mg/dL in youth with T1D. More advanced pubertal stages, longer disease duration, and less compliance were associated with less improvement
Study context
- Population
- Youth with T1D switching to MiniMed 780G, AWeSoMe Group; 59% females, median age 13.9 years, high socioeconomic background
- Participants
- 22 participants
- Exposure
- MiniMed 780G advanced hybrid closed-loop (AHCL): end of follow-up vs baseline
- Outcome
- Time in range (TIR) 70-180 mg/dL
- Follow-up
- Baseline to end
Methodological detailsreal-life, multicenter
- Real-life
- Multicenter
Main finding
As reported in the abstract
P = 0.008
Observational data: associations, not effects.
Further findings
| Outcome | End of follow-up | Baseline | P value |
|---|---|---|---|
| TAR >180 mg/dL · baseline to end of follow-upDecreased | 22% (IQR 14–35) | 28% (IQR 20–46) | P = 0.047 |
Correlates of glycemic outcomes
- Advanced pubertal stage correlated with less improvement in ΔTAR>180 mg/dL
- r = 0.47, P = 0.05
- Advanced pubertal stage correlated with less continuous glucose monitoring (CGM) usage
- r = −0.57, P = 0.05
- Longer disease duration associated with less improvement in ΔTAR180-250 mg/dL
- r = 0.48, P = 0.05
- Lower pump site change frequency associated with higher GMI
- r = 0.5, P = 0.03
- Lower pump site change frequency associated with lower TIR70-180 mg/dL
- r = −0.52, P = 0.08
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
MiniMed 780G Advanced Hybrid Closed-Loop System Outcomes According to Pubertal Status: Awesome Study Group Real-Life Experience. Diabetes Technol Ther. Published 14 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →